-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
-
Summary
-
Kiromic Biopharma, Inc. quarterly Goodwill history and growth rate from Q3 2021 to Q4 2022.
- Kiromic Biopharma, Inc. Goodwill for the quarter ending December 31, 2022 was $0.000.